CN121695144A - 包含氟马西尼和纳曲酮的组合物及其使用方法 - Google Patents

包含氟马西尼和纳曲酮的组合物及其使用方法

Info

Publication number
CN121695144A
CN121695144A CN202610170303.0A CN202610170303A CN121695144A CN 121695144 A CN121695144 A CN 121695144A CN 202610170303 A CN202610170303 A CN 202610170303A CN 121695144 A CN121695144 A CN 121695144A
Authority
CN
China
Prior art keywords
naltrexone
flumazenil
micrograms
combination
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202610170303.0A
Other languages
English (en)
Chinese (zh)
Inventor
L·E·罗德尼
D·J·扎纳尔杜
J·奇克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Treze Pharmaceuticals Private Ltd
Original Assignee
Treze Pharmaceuticals Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904390A external-priority patent/AU2020904390A0/en
Application filed by Treze Pharmaceuticals Private Ltd filed Critical Treze Pharmaceuticals Private Ltd
Publication of CN121695144A publication Critical patent/CN121695144A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202610170303.0A 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法 Pending CN121695144A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2020904390 2020-11-27
AU2020904390A AU2020904390A0 (en) 2020-11-27 Compositions and methods
PCT/AU2021/051413 WO2022109677A1 (en) 2020-11-27 2021-11-26 Compositions comprising flumazenil and naltrexone and methods for use thereof
CN202180078969.9A CN116648246A (zh) 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180078969.9A Division CN116648246A (zh) 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN121695144A true CN121695144A (zh) 2026-03-20

Family

ID=81753640

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202610170303.0A Pending CN121695144A (zh) 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法
CN202180078969.9A Pending CN116648246A (zh) 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180078969.9A Pending CN116648246A (zh) 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法

Country Status (9)

Country Link
US (4) US12521401B2 (cg-RX-API-DMAC7.html)
EP (1) EP4251168A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024501919A (cg-RX-API-DMAC7.html)
KR (1) KR20230110793A9 (cg-RX-API-DMAC7.html)
CN (2) CN121695144A (cg-RX-API-DMAC7.html)
AU (2) AU2021388076B2 (cg-RX-API-DMAC7.html)
CA (1) CA3201498A1 (cg-RX-API-DMAC7.html)
IL (1) IL303117A (cg-RX-API-DMAC7.html)
WO (1) WO2022109677A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106574A1 (en) * 2023-11-14 2025-05-22 Aardwolf Therapeutics, Inc. Flumazenil for treating post-traumatic stress disorder and anxiety
USD1127473S1 (en) * 2023-12-28 2026-05-26 Ceragem Co., Ltd. Easy chair
JP1807091S (ja) * 2023-12-28 2025-08-26 安楽椅子
JP1807096S (ja) * 2023-12-28 2025-08-26 安楽椅子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
ES2289935B1 (es) 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
WO2010094074A1 (en) * 2009-02-20 2010-08-26 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20150111916A9 (en) * 2010-04-29 2015-04-23 Annette Channa Toledano Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
CA2899455C (en) * 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
WO2014186824A1 (en) * 2013-05-20 2014-11-27 Palmaya Pty Ltd Treatment of neurological and other disorders
EP3057596A4 (en) * 2013-10-14 2017-03-29 Palmaya Pty Ltd Compositions and methods of administering same
US20220152044A1 (en) * 2019-03-14 2022-05-19 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system

Also Published As

Publication number Publication date
US12521401B2 (en) 2026-01-13
EP4251168A4 (en) 2024-11-06
WO2022109677A1 (en) 2022-06-02
AU2021388076B2 (en) 2025-08-14
IL303117A (en) 2023-07-01
US20240000796A1 (en) 2024-01-04
CN116648246A (zh) 2023-08-25
JP2024501919A (ja) 2024-01-17
US20260102405A1 (en) 2026-04-16
KR20230110793A (ko) 2023-07-25
KR20230110793A9 (ko) 2024-11-13
CA3201498A1 (en) 2022-06-02
US20260166054A1 (en) 2026-06-18
AU2021388076A1 (en) 2023-06-15
US20260166053A1 (en) 2026-06-18
AU2021388076A9 (en) 2024-08-08
EP4251168A1 (en) 2023-10-04
AU2025267401A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
AU2021388076B2 (en) Compositions comprising flumazenil and naltrexone and methods for use thereof
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
CN1132581C (zh) 含米尔塔扎平和一种或多种选择性5-羟色胺再摄取抑制剂的药物组合物
US10813928B2 (en) Aripiprazole formulations having increased injection speeds
CN102133171A (zh) 延缓释放阿立哌唑的可注射组合物
JP2021528495A (ja) ケタミンを含む新規製剤
JP2010065060A (ja) 心不全処置のための複合治療
RU2268725C2 (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
EP2670405B1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
CA2811345C (en) Compound composition for inhalation used for treating asthma
US20170065579A1 (en) Sustained Release Low Dose Formulations and Uses Thereof
WO2012129232A1 (en) Compositions for the treatment of psychotic or neurological disorders
WO2022123607A1 (en) Pharmaceutical formulations of esketamine
CN1946292B (zh) 减少共同滥用可能性的方法
JP2015519332A (ja) 鼻腔適用のための組成物
HK1100840A (en) Compositions and methods to treat recurrent medical conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination